Archives of Neuroscience

Published by: Kowsar

Deficits in Striatal Dopamine and Hippocampal Serotonin Following Induction of Anxiety/Depressive-Like Behaviors by Bisphenol A

Meng Jia 1 and Julian Pittman 1 , *
Authors Information
1 Department of Biological and Environmental Sciences, Troy University, Troy, AL 36083, USA
Article information
  • Archives of Neuroscience: January 01, 2015, 2 (1); e18555
  • Published Online: January 1, 2015
  • Article Type: Research Article
  • Received: February 26, 2014
  • Revised: March 17, 2014
  • Accepted: March 20, 2014
  • DOI: 10.5812/archneurosci.18555

To Cite: Jia M, Pittman J. Deficits in Striatal Dopamine and Hippocampal Serotonin Following Induction of Anxiety/Depressive-Like Behaviors by Bisphenol A, Arch Neurosci. 2015 ; 2(1):e18555. doi: 10.5812/archneurosci.18555.

Abstract
Copyright © 2015, Tehran University of Medical Sciences. This is an open-access article distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 International License (http://creativecommons.org/licenses/by-nc/4.0/) which permits copy and redistribute the material just in noncommercial usages, provided the original work is properly cited.
1. Background
2. Objectives
3. Patients and Methods
4. Results
5. Discussion
Acknowledgements
Footnotes
References
  • 1. Meireles J, Massano J. Cognitive impairment and dementia in Parkinson's disease: clinical features, diagnosis, and management. Front Neurol. 2012; 3: 88[DOI][PubMed]
  • 2. Ohno Y. Mapping the progress of Alzheimer's and Parkinson's disease. 2002; : 423-8[DOI]
  • 3. Samii A, Nutt JG, Ransom BR. Parkinson's disease. Lancet. 2004; 363(9423): 1783-93[DOI][PubMed]
  • 4. Richard IH, Schiffer RB, Kurlan R. Anxiety and Parkinson's disease. J Neuropsychiatry Clin Neurosci. 1996; 8(4): 383-92[PubMed]
  • 5. Ishibashi T, Ohno Y. Antiparkinsonian actions of a selective 5-HT 1A agonist, tandospirone, in rats. Biogenic Amines, 18. 2004; 3(6): 329-38[DOI]
  • 6. Matsubara K, Shimizu K, Suno M, Ogawa K, Awaya T, Yamada T, et al. Tandospirone, a 5-HT1A agonist, ameliorates movement disorder via non-dopaminergic systems in rats with unilateral 6-hydroxydopamine-generated lesions. Brain Res. 2006; 1112(1): 126-33[DOI][PubMed]
  • 7. Mignon L, Wolf WA. Postsynaptic 5-HT(1A) receptors mediate an increase in locomotor activity in the monoamine-depleted rat. Psychopharmacology (Berl). 2002; 163(1): 85-94[DOI][PubMed]
  • 8. Ohno Y. New insight into the therapeutic role of 5-HT1A receptors in central nervous system disorders. Cent Nerv Syst Agents Med Chem. 2010; 10(2): 148-57[PubMed]
  • 9. Ohno Y, Shimizu S, Imaki J, Ishihara S, Sofue N, Sasa M, et al. Evaluation of the antibradykinetic actions of 5-HT1A agonists using the mouse pole test. Prog Neuropsychopharmacol Biol Psychiatry. 2008; 32(5): 1302-7[DOI][PubMed]
  • 10. Bishop C, Krolewski DM, Eskow KL, Barnum CJ, Dupre KB, Deak T, et al. Contribution of the striatum to the effects of 5-HT1A receptor stimulation in L-DOPA-treated hemiparkinsonian rats. J Neurosci Res. 2009; 87(7): 1645-58[DOI][PubMed]
  • 11. Cheshire PA, Williams DR. Serotonergic involvement in levodopa-induced dyskinesias in Parkinson's disease. J Clin Neurosci. 2012; 19(3): 343-8[DOI][PubMed]
  • 12. Dupre KB, Eskow KL, Steiniger A, Klioueva A, Negron GE, Lormand L, et al. Effects of coincident 5-HT1A receptor stimulation and NMDA receptor antagonism on L-DOPA-induced dyskinesia and rotational behaviors in the hemi-parkinsonian rat. Psychopharmacology (Berl). 2008; 199(1): 99-108[DOI][PubMed]
  • 13. Tomiyama M, Kimura T, Maeda T, Kannari K, Matsunaga M, Baba M. A serotonin 5-HT1A receptor agonist prevents behavioral sensitization to L-DOPA in a rodent model of Parkinson's disease. Neurosci Res. 2005; 52(2): 185-94[DOI][PubMed]
  • 14. Chen CP, Alder JT, Bray L, Kingsbury AE, Francis PT, Foster OJ. Post-synaptic 5-HT1A and 5-HT2A receptors are increased in Parkinson's disease neocortex. Ann N Y Acad Sci. 1998; 861: 288-9[PubMed]
  • 15. Huot P, Johnston TH, Visanji NP, Darr T, Pires D, Hazrati LN, et al. Increased levels of 5-HT1A receptor binding in ventral visual pathways in Parkinson's disease. Mov Disord. 2012; 27(6): 735-42[DOI][PubMed]
  • 16. Smith GS, Dewey SL, Brodie JD, Logan J, Vitkun SA, Simkowitz P, et al. Serotonergic modulation of dopamine measured with [11C]raclopride and PET in normal human subjects. Am J Psychiatry. 1997; 154(4): 490-6[PubMed]
  • 17. Willner P, D'Aquila PS, Coventry T, Brain P. Loss of social status: preliminary evaluation of a novel animal model of depression. J Psychopharmacol. 1995; 9(3): 207-13[DOI][PubMed]
  • 18. Roy A, Pickar D, Linnoila M, Doran AR, Ninan P, Paul SM. Cerebrospinal fluid monoamine and monoamine metabolite concentrations in melancholia. Psychiatry Res. 1985; 15(4): 281-92[PubMed]
  • 19. Bowden C, Cheetham SC, Lowther S, Katona CL, Crompton MR, Horton RW. Reduced dopamine turnover in the basal ganglia of depressed suicides. Brain Res. 1997; 769(1): 135-40[PubMed]
  • 20. Van den Belt K, Verheyen R, Witters H. Comparison of vitellogenin responses in zebrafish and rainbow trout following exposure to environmental estrogens. Ecotoxicol Environ Saf. 2003; 56(2): 271-81[PubMed]
  • 21. Villeneuve DL, Garcia-Reyero N, Escalon BL, Jensen KM, Cavallin JE, Makynen EA, et al. Ecotoxicogenomics to support ecological risk assessment: a case study with bisphenol A in fish. Environ Sci Technol. 2012; 46(1): 51-9[DOI][PubMed]
  • 22. vom Saal FS, Akingbemi BT, Belcher SM, Birnbaum LS, Crain DA, Eriksen M, et al. Chapel Hill bisphenol A expert panel consensus statement: integration of mechanisms, effects in animals and potential to impact human health at current levels of exposure. Reprod Toxicol. 2007; 24(2): 131-8[DOI][PubMed]
  • 23. Levin ED, Bencan Z, Cerutti DT. Anxiolytic effects of nicotine in zebrafish. Physiol Behav. 2007; 90(1): 54-8[DOI][PubMed]
  • 24. Tracker. 2013;
Creative Commons License Except where otherwise noted, this work is licensed under Creative Commons Attribution Non Commercial 4.0 International License .
Readers' Comments